Welcome to Merz Therapeutics North America

Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is a global healthcare leader dedicated to improving the lives of patients around the world. With our relentless research, development, and culture of innovation, we strive to serve unmet patient needs and realize better outcomes.

Our Merz Therapeutics North America business is comprised of affiliates in the U.S. and Canada and has regional headquarters in Raleigh, N.C.

News

FDA APPROVES FIRST PEDIATRIC INDICATION FOR XEOMIN® (incobotulinumtoxinA) FOR THE TREATMENT OF UPPER LIMB SPASTICITY, EXCLUDING SPASTICITY CAUSED BY CEREBRAL PALSY

RALEIGH, N.C., August 19, 2020

Merz Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for the first pediatric indication for XEOMIN® (incobotulinumtoxinA), for the treatment of patients aged 2 years and older with upper limb spasticity, excluding spasticity caused by cerebral palsy.

Xeomin® (IncobotulinumtoxinA) Celebrates 10 Years of Meeting the Needs of Patients Suffering from Movement Disorders

RALEIGH, N.C., July 28, 2020

Merz Therapeutics is commemorating today the 10th anniversary of the first therapeutic approval of XEOMIN by the U.S. Food and Drug Administration.

MERZ FORMS FULLY FOCUSED GLOBAL MEDICAL AESTHETICS BUSINESS: MERZ AESTHETICS

RALEIGH, N.C., November 12, 2019

Merz, a global leader in the field of aesthetics and neurotoxins, today announced plans to reorganize into three independently operating businesses: medical aesthetics, therapeutics and consumer care.

Contact Us

Title*
Name*
Phone*
Email*
City*
State*
Topic*
Message*
CAPTCHA
Comments
This field is for validation purposes and should be left unchanged.

* mandatory fields

Please note that if you submit information to Merz all materials submitted by electronic or physical communication will be deemed non-confidential. Do not submit any information or other materials that you consider to be confidential or proprietary. While we have no intention to publicly disclose any details of your proposal, we may refer to select experts within or outside the Merz network for evaluation.